Dai X - Search Results

1

β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis.

Wu Z, Wu H, Wang Z, Li H, Gu H, Xia E, Yan C, Dai Y, Liu C, Wang X, Lv L, Bao J, Wang O, Dai X. Wu Z, et al. Among authors: dai x, dai y. Phytomedicine. 2023 Jun;114:154769. doi: 10.1016/j.phymed.2023.154769. Epub 2023 Mar 15. Phytomedicine. 2023. PMID: 36940580

2

The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.

Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM. Lin KL, et al. Ann Surg Oncol. 2010 Dec;17(12):3294-300. doi: 10.1245/s10434-010-1129-6. Epub 2010 Oct 15. Ann Surg Oncol. 2010. PMID: 20953721

3

Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.

Zhou YL, Zhang W, Gao EL, Dai XX, Yang H, Zhang XH, Wang OC. Zhou YL, et al. Asian Pac J Cancer Prev. 2012;13(4):1267-72. doi: 10.7314/apjcp.2012.13.4.1267. Asian Pac J Cancer Prev. 2012. PMID: 22799316 Free article.

4

Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.

Zhou YL, Liu C, Dai XX, Zhang XH, Wang OC. Zhou YL, et al. Med Oncol. 2012 Dec;29(5):3360-6. doi: 10.1007/s12032-012-0315-8. Epub 2012 Aug 2. Med Oncol. 2012. PMID: 22855362

5

Effectiveness of OK-432 (Sapylin) to reduce seroma formation after axillary lymphadenectomy for breast cancer.

Yang Y, Gao E, Liu X, Ye Z, Chen Y, Li Q, Qu J, Dai X, Wang O, Pan Y, Zhang X. Yang Y, et al. Among authors: dai x. Ann Surg Oncol. 2013 May;20(5):1500-4. doi: 10.1245/s10434-012-2728-1. Epub 2012 Oct 28. Ann Surg Oncol. 2013. PMID: 23104710 Clinical Trial.

6

Co-expression networks revealed potential core lncRNAs in the triple-negative breast cancer.

Yang F, Liu YH, Dong SY, Yao ZH, Lv L, Ma RM, Dai XX, Wang J, Zhang XH, Wang OC. Yang F, et al. Gene. 2016 Oct 15;591(2):471-7. doi: 10.1016/j.gene.2016.07.002. Epub 2016 Jul 2. Gene. 2016. PMID: 27380926

7

Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancer.

Yang F, Lv SX, Lv L, Liu YH, Dong SY, Yao ZH, Dai XX, Zhang XH, Wang OC. Yang F, et al. Onco Targets Ther. 2016 Nov 15;9:7039-7045. doi: 10.2147/OTT.S110055. eCollection 2016. Onco Targets Ther. 2016. PMID: 27895496 Free PMC article.

8

Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.

Dai X, Yin C, Guo G, Zhang Y, Zhao C, Qian J, Wang O, Zhang X, Liang G. Dai X, et al. Toxicol Appl Pharmacol. 2018 Nov 1;358:110-119. doi: 10.1016/j.taap.2018.09.005. Epub 2018 Sep 5. Toxicol Appl Pharmacol. 2018. PMID: 30195018

9

Osthole inhibits triple negative breast cancer cells by suppressing STAT3.

Dai X, Yin C, Zhang Y, Guo G, Zhao C, Wang O, Xiang Y, Zhang X, Liang G. Dai X, et al. J Exp Clin Cancer Res. 2018 Dec 22;37(1):322. doi: 10.1186/s13046-018-0992-z. J Exp Clin Cancer Res. 2018. PMID: 30577812 Free PMC article.

10

Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.

Yin C, Dai X, Huang X, Zhu W, Chen X, Zhou Q, Wang C, Zhao C, Zou P, Liang G, Rajamanickam V, Wang O, Zhang X, Cui R. Yin C, et al. Among authors: dai x. J Cell Mol Med. 2019 Mar;23(3):2194-2206. doi: 10.1111/jcmm.14139. Epub 2019 Jan 4. J Cell Mol Med. 2019. PMID: 30609207 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,484 results

Search Page

Filters